Data | Hora | Fonte | Título | Código | Companhia |
17/09/2010 | 17:14 | Edgar (US Regulatory) | Amended Current report filing (8-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/09/2010 | 17:13 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/09/2010 | 18:40 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/09/2010 | 10:00 | Business Wire | Allos Therapeutics to Present at Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
09/09/2010 | 14:29 | Business Wire | Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/09/2010 | 18:50 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/09/2010 | 17:19 | Edgar (US Regulatory) | Amended Annual Report (10-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/07/2010 | 17:17 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (S-8) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 08:53 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 08:30 | Business Wire | Allos Therapeutics Reports Second Quarter 2010 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 08:00 | Business Wire | Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
12/07/2010 | 10:00 | Business Wire | Allos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/07/2010 | 18:15 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/06/2010 | 10:00 | Business Wire | Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/06/2010 | 12:45 | Business Wire | Allos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/06/2010 | 10:00 | Business Wire | Allos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/06/2010 | 10:00 | Business Wire | Allos Therapeutics to Present at Four Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/06/2010 | 10:00 | Business Wire | Allos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology & the Congress of the ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/05/2010 | 10:00 | Business Wire | Allos Therapeutics to Present at the Citi Investment Research Global Health Care Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
18/05/2010 | 09:52 | Dow Jones News | Allos Gets Orphan-Drug Designation For Bladder Cancer Drug | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
18/05/2010 | 09:00 | Business Wire | Allos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation for the Treatment of Bladder Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
10/05/2010 | 16:42 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/05/2010 | 17:00 | Business Wire | Allos Therapeutics Reports First Quarter 2010 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/05/2010 | 16:22 | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/04/2010 | 07:06 | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
27/04/2010 | 09:00 | Business Wire | Allos Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
21/04/2010 | 09:00 | Business Wire | Allos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
09/04/2010 | 17:34 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/03/2010 | 18:46 | Edgar (US Regulatory) | Annual Report (10-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/03/2010 | 18:00 | Business Wire | Allos Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |